+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Melanoma"

From
From
Prostate Cancer - Competitive landscape, 2024 - Product Thumbnail Image

Prostate Cancer - Competitive landscape, 2024

  • Clinical Trials
  • November 2024
  • 450 Pages
  • Global
From
From
2022 ASCO Weekend Update - Product Thumbnail Image

2022 ASCO Weekend Update

  • Newsletter
  • June 2025
  • 88 Pages
  • Global
From
Immuno-Oncology Clinical Trials Market Report 2023-2033 - Product Thumbnail Image

Immuno-Oncology Clinical Trials Market Report 2023-2033

  • Report
  • September 2023
  • 249 Pages
  • Global
From
Monoclonal Antibodies for Oncology: Global Markets - Product Thumbnail Image

Monoclonal Antibodies for Oncology: Global Markets

  • Report
  • June 2022
  • 124 Pages
  • Global
From
Oncology Biomarkers: Global Markets - Product Thumbnail Image

Oncology Biomarkers: Global Markets

  • Report
  • June 2023
  • 186 Pages
  • Global
From
From
Immuno-oncology Market - Product Thumbnail Image

Immuno-oncology Market

  • Report
  • January 2024
  • 200 Pages
  • Global
From
From
From
From
From
From
Loading Indicator

Melanoma is a type of cancer that affects the skin and is the most serious form of skin cancer. It is caused by the uncontrolled growth of pigment-producing cells, known as melanocytes. Melanoma is the fifth most common cancer in the United States, with an estimated 87,110 new cases in 2020. It is also the leading cause of death from skin disease. The melanoma market within the oncology space is a rapidly growing segment, driven by the increasing prevalence of the disease and the development of new treatments. The market is expected to be driven by the increasing adoption of targeted therapies, immunotherapies, and combination therapies. Additionally, the increasing focus on personalized medicine and the development of novel drug delivery systems are expected to drive the market. Some of the key players in the melanoma market include Bristol-Myers Squibb, Merck & Co., Novartis, Roche, Pfizer, and Eli Lilly. Show Less Read more